143 related articles for article (PubMed ID: 9004296)
1. 99Tcm-DTPMP as a skeletal scintigraphy agent: distribution in rats in comparison with 99Tcm-MDP.
Láznícek M; Láznícková A; Budský F
Nucl Med Commun; 1996 Dec; 17(12):1016-20. PubMed ID: 9004296
[TBL] [Abstract][Full Text] [Related]
2. 99Tcm-citrate: a new bone imaging radiopharmaceutical.
Bhatnagar A; Mishra P; Sharma R; Chuttani K; Chakravarty K; Jain CM; Mondal A; Chopra MK; Gupta A
Nucl Med Commun; 1999 Nov; 20(11):1067-76. PubMed ID: 10572918
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.
Sahin M; Basoglu T; Bernay I; Yapici O; Canbaz F; Yalin T
Nucl Med Commun; 2000 Mar; 21(3):251-8. PubMed ID: 10823327
[TBL] [Abstract][Full Text] [Related]
4. Clinical comparison of bone scintigraphy with 99Tcm-DPD, 99Tcm-HDP and 99Tcm-MDP.
Bergqvist L; Brismar J; Cederquist E; Darte L; Naversten Y; Palmer J
Acta Radiol Diagn (Stockh); 1984; 25(3):217-23. PubMed ID: 6236672
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 99Tcm-labelled human immunoglobulin in animal models of experimentally induced inflammatory lesions.
Shimpi HH; Noronha OP; Samuel AM
Nucl Med Commun; 1995 Oct; 16(10):846-52. PubMed ID: 8570115
[TBL] [Abstract][Full Text] [Related]
6. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
7. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
Lantto T; Vorne M; Mokka R; Vähätalo S
Acta Radiol; 1987; 28(5):631-3. PubMed ID: 2960361
[TBL] [Abstract][Full Text] [Related]
8. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
9. A computer assisted comparison of 99Tcm-methylene-diphosphonate and 99Tcm-pyrophosphate bone imaging.
Büll U; Pfeifer JP; Niendorf HP; Tongendorff J
Br J Radiol; 1977 Sep; 50(597):629-36. PubMed ID: 198055
[TBL] [Abstract][Full Text] [Related]
10. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
Ghiron J; Volkert WA; Garlich J; Holmes RA
Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
[TBL] [Abstract][Full Text] [Related]
12. In vitro stability of 99Tcm bone scan preparations from different manufacturers measured by various radiopharmaceutical parameters.
Pauwels EK; Feitsma RI
Nucl Med Commun; 1984 Jul; 5(7):467-72. PubMed ID: 6099535
[TBL] [Abstract][Full Text] [Related]
13. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
Chang CP; Liu RS; Yu SM; Wynchank S; Chu LS; Shiau HY; Cheng TC
Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP.
Arteaga de Murphy C; Meléndez-Alafort L; Montoya-Molina CE; Sepúlveda-Méndez J
Nucl Med Biol; 1997 Jan; 24(1):27-33. PubMed ID: 9080472
[TBL] [Abstract][Full Text] [Related]
16. A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration.
Moore AE; Blake GM; Fogelman I
Nucl Med Commun; 2007 Mar; 28(3):187-92. PubMed ID: 17264777
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of labelled small peptide complexes for imaging agents with technetium-99m and biodistribution in mice.
Qi CM; Guo XF; Zhang HB; Li B; Jin W; Dai M
Yao Xue Xue Bao; 2002 Jul; 37(7):522-6. PubMed ID: 12914321
[TBL] [Abstract][Full Text] [Related]
18. Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study.
Ozdogan O; Ertay T; Arslan G; Sisman AR; Capa Kaya G; Yilmaz O; Coker C; Gure A; Durak H
Ann Nucl Med; 2008 Jun; 22(5):357-62. PubMed ID: 18600412
[TBL] [Abstract][Full Text] [Related]
19. The effect of mitomycin-C on the biodistribution of 99Tcm-MDP in Balb/c mice.
Gomes ML; de Souza Braga AC; de Mattos DM; de Souza Freitas R; Boasquevisque EM; Bernardo-Filho M
Nucl Med Commun; 1998 Dec; 19(12):1177-9. PubMed ID: 9885808
[TBL] [Abstract][Full Text] [Related]
20. Bone-seeking properties of Tc-99m carbonyl diphosphonic acid, dihydroxy-methylene diphosphonic acid and monohydroxy-methylene phosphoinic acid: concise communication.
Wang TS; Fawwaz RA; Johnson LJ; Mojdehi GE; Johnson PM
J Nucl Med; 1980 Aug; 21(8):767-70. PubMed ID: 7400832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
